Abstract
Inflammatory bowel disease (IBD) is known as a chronic inflammation of gastrointestinal tract that its pathogenesis still is not completely understood. Several drug categories are used for management of IBD but there is no exact cure for the disease, however biological drugs targeting the inflammation of gut are on the center of attention. In investigating the anti-inflammatory drugs, phosphodiesterase inhibitors were found to be effective in different inflammatory disorders. Of them phosphodiesterase 4 (PDE4) inhibitors are considered for treatment of asthma and chronic obstructive pulmonary disease (COPD). Some of the PDE4 inhibitors showed promising efficacy in animal studies, however to date no phase III clinical study showed their effectiveness in IBD. The present study has the most relevant studies in this field. PDE4 inhibitors affect IBD in different ways including anti-inflammatory, anti-depressant, and anti-fibrotic effects. Unfortunately, the most common side effect of PDE4 inhibitors is nausea which limits its use. Tetomilast the second generation of PDE4 inhibitors showed promising effects in phase II studies with better safety profile. Other drugs in this class are ongoing phase II and III trials.
Keywords: Inflammatory bowel disease, phosphodiesterase 4 inhibitor, Crohn's disease, ulcerative colitis, Phosphodiesterase 4 Inhibitors, chronic inflammation, gastrointestinal tract, IBD, phosphodiesterase inhibitors, asthma, chronic obstructive pulmonary disease, Tetomilast, incontinence, abdominal pain, reactive oxygen metabolites, aminosalicylates, immunomodulators, Phosphodiesterase enzyme, neurodegeneration, immunomodulatory cells, NO synthesis, anti-TNF- antibody, hepatic fibrosis, growth factor-I, cyclic adenosine monophosphate, cyclic guanosine monophosphate, protein kinases, phosphorylation, rheumatoid arthritis, multiple sclerosis, endotoxin, Sildenafil, a PDE5 inhibitor, Roflumilast, rolipram, cilomilast, T-cell chemotaxis, isoenzymes
Current Pharmaceutical Design
Title: Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Volume: 16 Issue: 33
Author(s): Pooneh Salari-Sharif and Mohammad Abdollahi
Affiliation:
Keywords: Inflammatory bowel disease, phosphodiesterase 4 inhibitor, Crohn's disease, ulcerative colitis, Phosphodiesterase 4 Inhibitors, chronic inflammation, gastrointestinal tract, IBD, phosphodiesterase inhibitors, asthma, chronic obstructive pulmonary disease, Tetomilast, incontinence, abdominal pain, reactive oxygen metabolites, aminosalicylates, immunomodulators, Phosphodiesterase enzyme, neurodegeneration, immunomodulatory cells, NO synthesis, anti-TNF- antibody, hepatic fibrosis, growth factor-I, cyclic adenosine monophosphate, cyclic guanosine monophosphate, protein kinases, phosphorylation, rheumatoid arthritis, multiple sclerosis, endotoxin, Sildenafil, a PDE5 inhibitor, Roflumilast, rolipram, cilomilast, T-cell chemotaxis, isoenzymes
Abstract: Inflammatory bowel disease (IBD) is known as a chronic inflammation of gastrointestinal tract that its pathogenesis still is not completely understood. Several drug categories are used for management of IBD but there is no exact cure for the disease, however biological drugs targeting the inflammation of gut are on the center of attention. In investigating the anti-inflammatory drugs, phosphodiesterase inhibitors were found to be effective in different inflammatory disorders. Of them phosphodiesterase 4 (PDE4) inhibitors are considered for treatment of asthma and chronic obstructive pulmonary disease (COPD). Some of the PDE4 inhibitors showed promising efficacy in animal studies, however to date no phase III clinical study showed their effectiveness in IBD. The present study has the most relevant studies in this field. PDE4 inhibitors affect IBD in different ways including anti-inflammatory, anti-depressant, and anti-fibrotic effects. Unfortunately, the most common side effect of PDE4 inhibitors is nausea which limits its use. Tetomilast the second generation of PDE4 inhibitors showed promising effects in phase II studies with better safety profile. Other drugs in this class are ongoing phase II and III trials.
Export Options
About this article
Cite this article as:
Salari-Sharif Pooneh and Abdollahi Mohammad, Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review, Current Pharmaceutical Design 2010; 16 (33) . https://dx.doi.org/10.2174/138161210794079209
DOI https://dx.doi.org/10.2174/138161210794079209 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cholinergic Drugs as Therapeutic Tools in Inflammatory Diseases: Participation of Neuronal and Non-Neuronal Cholinergic Systems.
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Prostaglandin EP Receptor Subtypes Involved in Regulating HCO3- Secretion from Gastroduodenal Mucosa
Current Pharmaceutical Design Hepatocyte Growth Factor (HGF), an Endogenous Pulmotrophic Regulator, for the Rescue of Acute and Chronic Lung Diseases
Current Signal Transduction Therapy Activation of Macrophages: Establishing a Role for Polysaccharides in Drug Delivery Strategies Envisaging Antibacterial Therapy
Current Pharmaceutical Design In Vitro and In Vivo Experimental Model-based Approaches for Investigating Anti-inflammatory Properties of Coumarins
Current Medicinal Chemistry Impact of Surfactants on Skin Penetration of Dexpanthenol
Current Drug Delivery Use of Antibiotics in Bronchiectasis
Reviews on Recent Clinical Trials Novel and Current Treatment Concepts Using Pulmonary Drug Delivery
Current Pharmaceutical Design Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry 3,4-Dihydropyrimidin-2(1H)-one C5 Amides as Inhibitors of T NFα Production: Synthesis, Biological Evaluation and Molecular Modeling
Letters in Drug Design & Discovery A Review of Pharmacological Properties and Toxicological Effects of Adiantum capillus-veneris L.
Current Drug Discovery Technologies Vaccination and Induction of Autoimmune Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Mast Cell Tryptase β as a Target in Allergic Inflammation: An Evolving Story
Current Pharmaceutical Design Inflammaging and Proteases in Abdominal Aortic Aneurysm
Current Vascular Pharmacology Cancer Microbiome; Opportunities and Challenges
Endocrine, Metabolic & Immune Disorders - Drug Targets Binding Modes and Pharmacophoric Features of Muscarinic Antagonism and β2 Agonism (MABA) Conjugates
Current Topics in Medicinal Chemistry Hyperglycemia and Diabetes Induced by Glucocorticoids in Nondiabetic and Diabetic Patients: Revision of Literature and Personal Considerations
Current Pharmaceutical Biotechnology The Soluble CTLA-4 Receptor and its Emerging Role in Autoimmune Diseases
Current Immunology Reviews (Discontinued) Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Alpha-1 Antitrypsin Deficiency: Current Perspective from Genetics to Diagnosis and Therapeutic Approaches
Current Medicinal Chemistry